Eyebright Medical Technology Stock Current Valuation
| 688050 Stock | 90.61 1.90 2.05% |
Valuation analysis of Eyebright Medical helps investors to measure Eyebright Medical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Eyebright Medical's Cash And Short Term Investments are projected to increase significantly based on the last few years of reporting. The current year's Change In Cash is expected to grow to about 190.8 M, whereas Cash is forecasted to decline to about 308 M. Fundamental drivers impacting Eyebright Medical's valuation include:
Price Book 7.5247 | Enterprise Value 17.7 B | Enterprise Value Ebitda 40.807 | Price Sales 12.6438 | Trailing PE 46.4667 |
Fairly Valued
Today
Please note that Eyebright Medical's price fluctuation is very steady at this time. Calculation of the real value of Eyebright Medical is based on 3 months time horizon. Increasing Eyebright Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eyebright Medical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eyebright Stock. However, Eyebright Medical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 90.61 | Real 91.13 | Hype 90.76 | Naive 89.74 |
The real value of Eyebright Stock, also known as its intrinsic value, is the underlying worth of Eyebright Medical Company, which is reflected in its stock price. It is based on Eyebright Medical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Eyebright Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Eyebright Medical Technology helps investors to forecast how Eyebright stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eyebright Medical more accurately as focusing exclusively on Eyebright Medical's fundamentals will not take into account other important factors: Eyebright Medical Technology Company Current Valuation Analysis
Eyebright Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eyebright Medical Current Valuation | 17.66 B |
Most of Eyebright Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyebright Medical Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Eyebright Medical Technology has a Current Valuation of 17.66 B. This is 22.98% higher than that of the Health Care Equipment & Supplies sector and 93.19% higher than that of the Health Care industry. The current valuation for all China stocks is 6.25% lower than that of the firm.
Eyebright Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyebright Medical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyebright Medical could also be used in its relative valuation, which is a method of valuing Eyebright Medical by comparing valuation metrics of similar companies.Eyebright Medical is currently under evaluation in current valuation category among its peers.
Eyebright Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 17.66 B | ||||
| Shares Outstanding | 189.54 M | ||||
| Shares Owned By Insiders | 38.48 % | ||||
| Shares Owned By Institutions | 20.78 % | ||||
| Price To Book | 7.52 X | ||||
| Price To Sales | 12.64 X | ||||
| Revenue | 951.18 M | ||||
| Gross Profit | 491.15 M | ||||
| EBITDA | 506.62 M | ||||
| Net Income | 304.43 M | ||||
| Total Debt | 117.94 M | ||||
| Book Value Per Share | 12.29 X | ||||
| Cash Flow From Operations | 212.62 M | ||||
| Earnings Per Share | 1.95 X | ||||
| Target Price | 115.8 | ||||
| Number Of Employees | 2.07 K | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 17.17 B | ||||
| Total Asset | 3.06 B | ||||
| Retained Earnings | 647.18 M | ||||
| Working Capital | 645.1 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 3.06 B | ||||
| Last Dividend Paid | 0.27 |
About Eyebright Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyebright Medical Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyebright Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyebright Medical Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Eyebright Stock
Eyebright Medical financial ratios help investors to determine whether Eyebright Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eyebright with respect to the benefits of owning Eyebright Medical security.